The Roche healthcare group and medical device supplier Disetronic today announced plans for Roche to acquire Disetronic, the world’s second-biggest maker of insulin pumps.
According to a statement, Roche plans to offer shareholders two Roche non-voting equity securities and 670 Swiss francs in cash for each Disetronic share. Based on current estimates, the cost of the acquisition is expected to amount to 1,6 billion Swiss francs (US$1.18 billion).
Headquartered in Burgdorf, Switzerland, the Disetronic Group is one of the world’s leading suppliers of infusion and injection systems. After the transaction is finalised, Disetronic’s Infusion Systems division will become part of Roche Diagnostics’ Diabetes Care unit.
The proposed acquisition is said to have the support of Disetronic’s board of directors and is subject to approval by competition authorities and by a special meeting of Disentronic’s shareholders. For the acquisition to take place, Roche’s offer must be accepted by at least 80% of Disetronic’s shareholders.